Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORM MM26 Domain 1: selinexor + pomalidomide + dexamethasone for orphan relapsed/refractory multiple myeloma
ACTRN12622001313729Phase 2Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of selinexor, pomalidomide and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Stratum A response by end of cycle 4, Stratum B response by end of cycle 4 and 2 more. Started Aug 2023; status: terminated.
02
Drugs
selinexorpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12622001313729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001313729.